Sanofi Seeks Chinese Partners For R&D Work
This article was originally published in PharmAsia News
Executive Summary
Sanofi Aventis seeks to involve Chinese universities and laboratories in research partnerships by the end of this year, concentrating on cancer and rheumatoid arthritis treatments. The head of Sanofi's research and development said the company hopes the joint efforts with six Chinese institutions would help it discover new drugs. Marc Cluzel notes the Chinese government is investing in biological research and education he believes will make China a key resource for innovative new drugs by 2015. The Sanofi approach differs from other drug makers who plan to build R&D facilities in China. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.